Homepage
Medication Guide
How Effective is Lemborexant (Dayvigo) in Treatment?
Lemborexant (Dayvigo) is a novel orexin receptor antagonist that improves insomnia symptoms by regulating the wakefulness signaling pathway.How Effective is Lemborexant (Dayvigo) in Treatment?Improvem...
501
Thursday, September 11th, 2025, 15:59
Precautions for Lemborexant (Dayvigo) Use
Lemborexant (Dayvigo) is a selective orexin receptor antagonist that exerts its effect by blocking the orexin neuropeptide receptors OX1R and OX2R, which promote wakefulness.Precautions for Lemborexan...
502
Thursday, September 11th, 2025, 15:48
How to Use Lemborexant (Dayvigo)
Lemborexant (Dayvigo) is a selective orexin receptor antagonist indicated for the treatment of insomnia in adults (characterized by difficulty falling asleep or sleep maintenance disorders). It promot...
501
Thursday, September 11th, 2025, 15:44
Indications for Lemborexant (Dayvigo)
Lemborexant (Dayvigo) is a selective orexin receptor antagonist used for the treatment of insomnia in adults, particularly in patients with difficulty falling asleep and/or difficulty maintaining slee...
503
Thursday, September 11th, 2025, 15:38
Precautions for Opcapone (Ongentys) Use
Opcapone (Ongentys) is a selective and reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. As an adjunctive therapeutic agent to levodopa/carbidopa, it is used to improve "off&qu...
501
Thursday, September 11th, 2025, 15:32
How to Use Opcapone (Ongentys)
Opcapone (Ongentys) is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor. It is used as an adjunctive treatment to levodopa/carbidopa for improving "off" period sympto...
506
Thursday, September 11th, 2025, 15:14
Indications for Opcapone (Ongentys)
Opcapone (Ongentys) is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, used as an adjunctive treatment for Parkinson's disease (PD).Indications for Opcapone (Ongentys)Cor...
519
Thursday, September 11th, 2025, 14:59
Standard Dosage and Administration of Sotorasib (AMG510)
Sotorasib (AMG510) is a KRASG12C inhibitor indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRASG12C mutation.Standard Dosage and Administration of...
505
Wednesday, September 10th, 2025, 16:00
What is Sotorasib (AMG510)?
Sotorasib (AMG510) is a highly selective targeted drug for the KRASG12C mutation. Developed by Amgen Inc., it received accelerated approval from the U.S. FDA in 2021 for the treatment of non-small cel...
504
Wednesday, September 10th, 2025, 15:54
How to Use Sotorasib (AMG510)
Sotorasib (AMG510) is a KRASG12C inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.How to Use...
503
Wednesday, September 10th, 2025, 15:50
99 / 186
1852 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved